Remove tag ataxia
article thumbnail

PharmaShots Weekly Snapshots (June 12 – 16, 2023)

PharmaShots

Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B

FDA 40
article thumbnail

PharmaShots Weekly Snapshots (March 13 - 17, 2023)

PharmaShots

5-Adapted Bivalent Booster to Treat COVID-19 in Children ≤5 Years Date: Mar 15, 2023 | Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted 5-Adapted Bivalent Booster to Treat COVID-19 in Children ≤5 Years Date: Mar 15, 2023 | Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted

FDA 40
article thumbnail

HP&M Attorneys Receive Accolades: Top Lawyer Under 40 and WWL: Life Sciences 2023 Global Elite Thought Leader

The FDA Law Blog

Duchenne, Friederichs’s Ataxia, Sickle Cell Disease, Chagas, ALS). In addition to Mr. Karst, ten other HP&M Directors were tagged as “Recommended” by WWL: Life Sciences 2023: Ricardo Carvajal Robert A. Dormer Jeffrey N. Gibbs Paul M. Hyman Alan M. Kirschenbaum Allyson B. Mullen Frank J. Sasinowski Jeffrey K.

FDA 81